175 related articles for article (PubMed ID: 21910790)
1. Effect of fibrinolysis on bleeding phenotype in moderate and severe von Willebrand disease.
De Wee EM; Klaij K; Eikenboom HC; Van Der Bom JG; Fijnvandraat K; Laros-Van Gorkom BA; Mauser-Bunschoten EP; Meijer K; Goverde G; Van Der Linden PW; Rijken DC; Leebeek FW;
Haemophilia; 2012 May; 18(3):444-51. PubMed ID: 21910790
[TBL] [Abstract][Full Text] [Related]
2. Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease.
de Wee EM; Sanders YV; Mauser-Bunschoten EP; van der Bom JG; Degenaar-Dujardin ME; Eikenboom J; de Goede-Bolder A; Laros-van Gorkom BA; Meijer K; Hamulyák K; Nijziel MR; Fijnvandraat K; Leebeek FW;
Thromb Haemost; 2012 Oct; 108(4):683-92. PubMed ID: 22918553
[TBL] [Abstract][Full Text] [Related]
3. Plasma levels of plasminogen activator inhibitor-1 and bleeding phenotype in patients with von Willebrand disease.
Abdul S; Boender J; Malfliet JJMC; Eikenboom J; Fijn van Draat K; Mauser-Bunschoten EP; Meijer K; de Meris J; Laros-van Gorkom BAP; van der Bom JG; Leebeek FWG; Rijken DC; Uitte de Willige S;
Haemophilia; 2017 May; 23(3):437-443. PubMed ID: 28306198
[TBL] [Abstract][Full Text] [Related]
4. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
5. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681
[TBL] [Abstract][Full Text] [Related]
6. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
[TBL] [Abstract][Full Text] [Related]
7. Clinical diagnosis of von Willebrand disease.
Federici AB
Haemophilia; 2004 Oct; 10 Suppl 4():169-76. PubMed ID: 15479393
[TBL] [Abstract][Full Text] [Related]
8. Platelet von Willebrand factor determination does not improve the diagnosis of patients with suspected Type 1 von Willebrand disease.
Shihong I; Morris D; Konkle BA
Haemophilia; 2009 Jan; 15(1):131-4. PubMed ID: 18976254
[TBL] [Abstract][Full Text] [Related]
9. Thrombin-generating capacity in patients with von Willebrand's disease.
Rugeri L; Beguin S; Hemker C; Bordet JC; Fleury R; Chatard B; Negrier C; Dargaud Y
Haematologica; 2007 Dec; 92(12):1639-46. PubMed ID: 18055987
[TBL] [Abstract][Full Text] [Related]
10. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
11. Baseline factor VIII plasma levels and age at first bleeding in patients with severe forms of von Willebrand disease.
Siboni SM; Biguzzi E; Caiani V; Mistretta C; Bucciarelli P; Peyvandi F
Haemophilia; 2016 Jul; 22(4):564-9. PubMed ID: 26843468
[TBL] [Abstract][Full Text] [Related]
12. Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment.
Castaman G; Federici AB; Rodeghiero F; Mannucci PM
Haematologica; 2003 Jan; 88(1):94-108. PubMed ID: 12551832
[TBL] [Abstract][Full Text] [Related]
13. Assessing bleeding in von Willebrand disease with bleeding score.
Tosetto A; Castaman G; Rodeghiero F
Blood Rev; 2007 Mar; 21(2):89-97. PubMed ID: 16774804
[TBL] [Abstract][Full Text] [Related]
14. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
[TBL] [Abstract][Full Text] [Related]
15. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
Michiels JJ; Gadisseur A; Budde U; Berneman Z; van der Planken M; Schroyens W; van de Velde A; van Vliet H
Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467
[TBL] [Abstract][Full Text] [Related]
16. Reassessment of ABO blood group, sex, and age on laboratory parameters used to diagnose von Willebrand disorder: potential influence on the diagnosis vs the potential association with risk of thrombosis.
Favaloro EJ; Soltani S; McDonald J; Grezchnik E; Easton L; Favaloro JW
Am J Clin Pathol; 2005 Dec; 124(6):910-7. PubMed ID: 16416741
[TBL] [Abstract][Full Text] [Related]
17. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of highly purified, doubly virus-inactivated VWF/FVIII concentrates in inherited von Willebrand's disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score.
Federici AB; Barillari G; Zanon E; Mazzucconi MG; Musso R; Targhetta R; Mannucci PM
Haemophilia; 2010 Jan; 16(1):101-10. PubMed ID: 19811543
[TBL] [Abstract][Full Text] [Related]
19. Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance.
Castaman G; Tosetto A; Federici AB; Rodeghiero F
Thromb Haemost; 2011 Apr; 105(4):647-54. PubMed ID: 21264446
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand's disease: a prospective multi-centre study.
Dunkley S; Baker RI; Pidcock M; Price J; Seldon M; Smith M; Street A; Maher D; Barrese G; Stone C; Lloyd J
Haemophilia; 2010 Jul; 16(4):615-24. PubMed ID: 20331755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
